PRESS RELEASE published on 01/08/2024 at 14:00, 1 year 10 months ago Bold Strategies, Inc. Appoints Darcy Ramler as New CEO Bold Strategies, Inc. announces a major leadership transition as Darcy Ramler, currently the Chief Revenue Officer, is promoted to President and Chief Executive Officer, succeeding founder Allan Peretz who will transition to Executive Chairman. This marks the first-ever CEO transition in the company's history and signifies a significant milestone for the organization. Ramler's extensive expertise in commerce strategy and transformative leadership in major apparel companies, coupled with her proven success in business expansion, are set to propel BOLD's growth trajectory further. As the company continues to make its mark in the industry with significant accomplishments, including being listed on the Inc. 5000 list of America's fastest-growing private companies for two consecutive years and securing a $2.3 million investment in 2022, the new leadership promises an innovative and successful future for BOLD. Bold Strategies Inc Darcy Ramler Allan Peretz CEO Transition Commerce Growth Services
Published on 12/05/2025 at 02:35, 4 hours 3 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 38 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 33 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 38 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 7 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 47 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 12 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 23 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 27 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 23 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 38 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 38 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 53 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 53 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL